2 research outputs found
Autoantibodies to TP53 discriminate breast cancer sera from control sera.
<p>ROC curves showing the 43 HRN cases (black) and the 28 TN subset (blue) vs. 87 matched healthy controls.</p
Selection of 15 analytes and their sensitivity/specificity as serum markers.
<p>Data from 43 cases and 87 controls. Marker selection criteria: (1) serum marker potential in high-grade serous ovarian cancer and involvement in breast cancer; (2) transcript involved in breast cancer; (3) association with poor breast cancer outcome; (4) protein decreased in breast cancer tissue compared to normal breast.</p><p>Selection of 15 analytes and their sensitivity/specificity as serum markers.</p